600594 益佰制药
已收盘 08-20 15:00:00
资讯
新帖
简况
每周股票复盘:益佰制药(600594)两产品中选中成药集采
证券之星 · 08-09
每周股票复盘:益佰制药(600594)两产品中选中成药集采
股市必读:益佰制药新发布《贵州益佰制药股份有限公司关于产品中选全国中成药采购联盟集中采购(第二批接续)的公告》
证券之星 · 08-04
股市必读:益佰制药新发布《贵州益佰制药股份有限公司关于产品中选全国中成药采购联盟集中采购(第二批接续)的公告》
益佰制药(600594.SH):复方斑蝥胶囊等拟中选集中采购
智通财经 · 08-03
益佰制药(600594.SH):复方斑蝥胶囊等拟中选集中采购
异动快报:益佰制药(600594)7月27日9点40分触及涨停板
证券之星 · 07-27
异动快报:益佰制药(600594)7月27日9点40分触及涨停板
股市必读:益佰制药(600594)7月17日收盘跌6.09%,主力净流入130.93万元
证券之星 · 07-20
股市必读:益佰制药(600594)7月17日收盘跌6.09%,主力净流入130.93万元
每周股票复盘:益佰制药(600594)上半年预亏7400万至8880万元
证券之星 · 07-19
每周股票复盘:益佰制药(600594)上半年预亏7400万至8880万元
益佰制药(600594)披露2026年半年度业绩预告,7月14日股价上涨2.06%
证券之星 · 07-14
益佰制药(600594)披露2026年半年度业绩预告,7月14日股价上涨2.06%
益佰制药:公司未触及各类退市风险警示情形
证券之星 · 07-10
益佰制药:公司未触及各类退市风险警示情形
益佰制药(600594)披露回购股份注销暨股份变动公告,7月9日股价下跌0.32%
证券之星 · 07-09
益佰制药(600594)披露回购股份注销暨股份变动公告,7月9日股价下跌0.32%
益佰制药董事会选举窦啟玲为董事长
投资观察 · 07-07
益佰制药董事会选举窦啟玲为董事长
每周股票复盘:益佰制药(600594)完成董事会换届选举
证券之星 · 07-05
每周股票复盘:益佰制药(600594)完成董事会换届选举
益佰制药(600594)披露2026年第一次临时股东会决议公告,7月2日股价上涨1.61%
证券之星 · 07-02
益佰制药(600594)披露2026年第一次临时股东会决议公告,7月2日股价上涨1.61%
益佰制药最新公告:选举窦启玲为董事长
证券之星 · 07-02
益佰制药最新公告:选举窦启玲为董事长
每周股票复盘:益佰制药(600594)将召开临时股东会审议董监换届
证券之星 · 06-28
每周股票复盘:益佰制药(600594)将召开临时股东会审议董监换届
益佰制药(600594)披露2026年第一次临时股东会会议资料,6月26日股价下跌3.91%
证券之星 · 06-26
益佰制药(600594)披露2026年第一次临时股东会会议资料,6月26日股价下跌3.91%
益佰制药(600594)披露2026年第一次临时股东会通知,6月16日股价下跌1.52%
证券之星 · 06-16
益佰制药(600594)披露2026年第一次临时股东会通知,6月16日股价下跌1.52%
每周股票复盘:益佰制药(600594)拟注销753万回购股份
证券之星 · 05-24
每周股票复盘:益佰制药(600594)拟注销753万回购股份
益佰制药(600594)披露变更回购股份用途并注销暨通知债权人公告,5月20日股价下跌2.81%
证券之星 · 05-20
益佰制药(600594)披露变更回购股份用途并注销暨通知债权人公告,5月20日股价下跌2.81%
每周股票复盘:益佰制药(600594)将举办2025年度业绩说明会
证券之星 · 05-02
每周股票复盘:益佰制药(600594)将举办2025年度业绩说明会
益佰制药(600594)披露将参加2026年贵州辖区上市公司投资者集体接待日活动暨2025年度业绩说明会,4月30日股价下跌1.7%
证券之星 · 04-30
益佰制药(600594)披露将参加2026年贵州辖区上市公司投资者集体接待日活动暨2025年度业绩说明会,4月30日股价下跌1.7%
加载更多
公司概况
公司名称:
贵州益佰制药股份有限公司
所属行业:
医药制造业
上市日期:
2004-03-23
主营业务:
贵州益佰制药股份有限公司的主营业务是药品的研发、生产和销售,综合性医院、肿瘤专科医院、肿瘤放疗中心的运营与管理,开发、研制、生产及销售以苗药为特色的大健康产品。公司的主要产品是注射用洛铂、银杏达莫注射液、抗肿瘤类、心脑血管类、男科类、妇科类、其他、注射用瑞替普酶、科博肽、医疗服务、糖果、植物饮料、膏滋。
发行价格:
14.40
{"stockData":{"symbol":"600594","market":"SH","secType":"STK","nameCN":"益佰制药","latestPrice":3.88,"timestamp":1787209201000,"preClose":3.83,"halted":0,"volume":38995700,"delay":0,"changeRate":0.0131,"floatShares":784000000,"shares":784000000,"eps":-0.4459,"marketStatus":"已收盘","change":0.05,"latestTime":"08-20 15:00:00","open":3.9,"high":4.02,"low":3.87,"amount":154000000,"amplitude":0.0392,"askPrice":3.89,"askSize":177,"bidPrice":3.88,"bidSize":1460,"shortable":0,"etf":0,"ttmEps":-0.4459,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787275800000},"marketStatusCode":5,"adr":0,"adjPreClose":3.83,"symbolType":"stock","openAndCloseTimeList":[[1787189400000,1787196600000],[1787202000000,1787209200000]],"highLimit":4.21,"lowLimit":3.45,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":784393900,"isCdr":false,"pbRate":1.41,"roa":"--","roe":"--","epsLYR":-0.42,"committee":-0.250605,"marketValue":3043000000,"turnoverRate":0.0497,"status":0,"floatMarketCap":3043000000},"requestUrl":"/m/hq/s/600594","defaultTab":"news","newsList":[{"id":"2658731006","title":"每周股票复盘:益佰制药(600594)两产品中选中成药集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2658731006","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658731006?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:42","pubTimestamp":1786210931,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘,益佰制药报收于3.75元,较上周的3.56元上涨5.34%。本周,益佰制药8月7日盘中最高价报3.75元。益佰制药当前最新总市值29.41亿元,在中药板块市值排名55/66,在两市A股市值排名4331/5205。公司公告汇总贵州益佰制药股份有限公司公告,公司产品复方斑蝥胶囊和银杏达莫注射液中选全国中成药采购联盟集中采购。2025年度复方斑蝥胶囊销售收入为8,298.76万元,占营业收入的4.45%;银杏达莫注射液销售收入为13,089.18万元,占营业收入的7.03%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0070","600594","BK0028","BK0077","BK0039","BK0239","BK0060","BK0188","BK0097","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656767305","title":"股市必读:益佰制药新发布《贵州益佰制药股份有限公司关于产品中选全国中成药采购联盟集中采购(第二批接续)的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656767305","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656767305?lang=zh_cn&edition=full","pubTime":"2026-08-04 02:03","pubTimestamp":1785780199,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘,益佰制药报收于3.57元,上涨0.28%,换手率2.97%,成交量23.26万手,成交额8293.1万元。公司公告汇总贵州益佰制药股份有限公司关于产品中选全国中成药采购联盟集中采购的公告公司产品复方斑蝥胶囊和银杏达莫注射液中选全国中成药采购联盟集中采购,采购周期至2028年12月31日。2025年度复方斑蝥胶囊销售收入为8,298.76万元,占营业收入的4.45%;银杏达莫注射液销售收入为13,089.18万元,占营业收入的7.03%。2026年一季度两产品收入占比分别为4.88%和5.35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001537.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0012","BK0070","BK0060","BK0096","BK0028","BK0239","BK0077","BK0039","BK0188","600594"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656372805","title":"益佰制药(600594.SH):复方斑蝥胶囊等拟中选集中采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2656372805","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656372805?lang=zh_cn&edition=full","pubTime":"2026-08-03 21:51","pubTimestamp":1785765110,"startTime":"0","endTime":"0","summary":"智通财经APP讯,益佰制药(600594.SH)发布公告,公司于近日参加了全国中成药采购联盟集中采购(第二批接续)的投标工作,根据全国中成药联合采购办公室于近日发布的《关于公布全国中成药采购联盟集中采购中选品种供应清单的通知》,公司产品复方斑蝥胶囊、银杏达莫注射液中选本次接续采购。采购周期内,医疗机构将优先使用本次接续采购中选药品,并确保完成协议采购量。若公司后续签订采购合同并实施,将有利于进一步扩大中选产品的销售范围,提高中选产品的市场占有率,提升公司的品牌影响力,对公司长远发展产生积极影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0060","BK0096","BK0028","BK0077","BK0097","600594","BK0070","BK0039","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654932740","title":"异动快报:益佰制药(600594)7月27日9点40分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2654932740","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654932740?lang=zh_cn&edition=full","pubTime":"2026-07-27 09:47","pubTimestamp":1785116821,"startTime":"0","endTime":"0","summary":"证券之星7月27日盘中消息,9点40分益佰制药(600594)触及涨停板。其所属行业中药目前上涨。领涨股为陇神戎发。该股为医药,中药,民营医院概念热股,当日医药概念上涨2.58%,中药概念上涨2.37%,民营医院概念上涨2.19%。7月24日的资金流向数据方面,主力资金净流出465.23万元,占总成交额3.25%,游资资金净流入1035.08万元,占总成交额7.23%,散户资金净流出569.85万元,占总成交额3.98%。近5日资金流向一览见下表:益佰制药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700004025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","600594","BK0012","BK0188","BK0028","BK0060","BK0070","BK0096","BK0097","BK0039","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652571822","title":"股市必读:益佰制药(600594)7月17日收盘跌6.09%,主力净流入130.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652571822","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652571822?lang=zh_cn&edition=full","pubTime":"2026-07-20 02:40","pubTimestamp":1784486421,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,益佰制药报收于3.39元,下跌6.09%,换手率4.4%,成交量34.48万手,成交额1.19亿元。交易信息汇总股价提醒7月17日益佰制药收盘报3.39元,跌6.09%,当日成交1.19亿元。前10个交易日主力资金累计净流入145.32万元,股价累计下跌6.09%;融资余额累计减少510.28万元,融券余量累计减少2.32万股。资金流向7月17日主力资金净流入130.93万元,占总成交额0.0%;游资资金净流出352.5万元,占总成交额0.0%;散户资金净流入221.56万元,占总成交额0.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000001271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0096","BK0097","BK0188","BK0060","BK0070","BK0077","600594","BK0239","BK0039","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652258655","title":"每周股票复盘:益佰制药(600594)上半年预亏7400万至8880万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652258655","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652258655?lang=zh_cn&edition=full","pubTime":"2026-07-19 03:39","pubTimestamp":1784403548,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,益佰制药报收于3.39元,较上周的3.32元上涨2.11%。本周,益佰制药7月16日盘中最高价报3.64元。本周关注点业绩披露要点:益佰制药预计2026年上半年归属净利润亏损7400万元至8880万元。公司公告汇总贵州益佰制药股份有限公司预计2026年半年度实现归属于母公司所有者的净利润为-8,880万元到-7,400万元,扣除非经常性损益后的净利润为-9,720万元到-8,100万元,将出现亏损。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071900001332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0077","BK0239","BK0039","BK0096","BK0070","BK0097","600594","BK0060","BK0012","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651910422","title":"益佰制药(600594)披露2026年半年度业绩预告,7月14日股价上涨2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651910422","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651910422?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:35","pubTimestamp":1784039712,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘,益佰制药报收于3.47元,较前一交易日上涨2.06%,最新总市值为27.22亿元。该股当日开盘3.37元,最高3.47元,最低3.31元,成交额达1.03亿元,换手率为3.84%。近日,贵州益佰制药股份有限公司披露《2026年半年度业绩预告》。本期业绩预告未经注册会计师审计,具体财务数据以公司正式披露的2026年半年度报告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400049790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","BK0070","BK0028","BK0239","BK0077","BK0096","BK0012","600594","BK0039","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650018109","title":"益佰制药:公司未触及各类退市风险警示情形","url":"https://stock-news.laohu8.com/highlight/detail?id=2650018109","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650018109?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:25","pubTimestamp":1783679123,"startTime":"0","endTime":"0","summary":"证券之星消息,益佰制药(600594)07月10日在投资者关系平台上答复投资者关心的问题。投资者提问:益佰制药是不是要退市呀,这节奏不对劲吗?益佰制药回复:您好,公司未触及《上海证券交易所股票上市规则》规定的各类退市风险警示情形,感谢您的关注。本文数据来源于上海证券交易所e互动,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000036067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0077","BK0012","BK0028","BK0097","BK0239","600594","BK0039","BK0070","BK0188","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650920082","title":"益佰制药(600594)披露回购股份注销暨股份变动公告,7月9日股价下跌0.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650920082","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2650920082?lang=zh_cn&edition=full","pubTime":"2026-07-09 22:32","pubTimestamp":1783607534,"startTime":"0","endTime":"0","summary":"截至2026年7月9日收盘,益佰制药报收于3.15元,较前一交易日下跌0.32%,最新总市值为24.95亿元。近日,贵州益佰制药股份有限公司发布《关于实施回购股份注销暨股份变动的公告》。公告显示,公司将注销回购专用证券账户中的7,533,500股股份,占注销前总股本的0.95%。本次注销完成后,公司总股本将由791,927,400股变更为784,393,900股。公司已履行变更用途并注销的审批程序及债权人通知义务,未收到异议。注销不影响公司控制权、股权分布及上市条件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900042679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","600594","BK0097","BK0188","BK0096","BK0070","BK0039","BK0060","BK0028","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175747044","title":"益佰制药董事会选举窦啟玲为董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=1175747044","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175747044?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:46","pubTimestamp":1783413978,"startTime":"0","endTime":"0","summary":"7月2日,贵州益佰制药股份有限公司宣布,公司董事会已选举窦啟玲女士担任董事长一职。\n此次人事变动标志着公司治理结构的关键调整。窦啟玲女士的当选,预计将为这家上市药企的未来战略方向带来新的视角与领导力。董事会的这一决定,旨在强化公司决策层的稳定性与专业性,以应对当前医药行业复杂多变的市场环境与监管要求。\n作为一家在上海证券交易所上市的公司,益佰制药此举是其完善公司治理、推动长期发展的组成部分。市场将密切关注新任董事长就任后,公司在业务拓展、研发创新及财务表现等方面的后续动向。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0039","BK0239","BK0096","BK0077","BK0060","600594","BK0012","BK0188","BK0097","BK0028","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649692787","title":"每周股票复盘:益佰制药(600594)完成董事会换届选举","url":"https://stock-news.laohu8.com/highlight/detail?id=2649692787","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649692787?lang=zh_cn&edition=full","pubTime":"2026-07-05 04:30","pubTimestamp":1783197028,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,益佰制药报收于3.2元,较上周的2.95元上涨8.47%。公司公告汇总贵州益佰制药股份有限公司于2026年7月2日召开第九届董事会第一次会议,选举窦启玲为公司董事长,窦雅琪为副董事长。上述人员任期均为三年,自董事会审议通过之日起至第九届董事会任期届满为止。其任职资格已于2026年6月12日经第八届董事会提名委员会审查通过。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500001612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0039","BK0188","BK0070","BK0096","BK0239","600594","BK0012","BK0060","BK0028","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648314689","title":"益佰制药(600594)披露2026年第一次临时股东会决议公告,7月2日股价上涨1.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648314689","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648314689?lang=zh_cn&edition=full","pubTime":"2026-07-02 23:13","pubTimestamp":1783005193,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘,益佰制药报收于3.16元,较前一交易日上涨1.61%,最新总市值为25.02亿元。近日,贵州益佰制药股份有限公司披露《2026年第一次临时股东会决议公告》。公告显示,公司于2026年7月2日召开2026年第一次临时股东会,审议通过了关于选举公司第九届董事会非独立董事和独立董事的议案。会议由董事会召集,董事长窦启玲主持,采用现场与网络投票结合方式表决,出席会议股东所持表决权股份占公司总股本的24.3437%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0012","BK0188","600594","BK0060","BK0077","BK0070","BK0039","BK0096","BK0097","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648017655","title":"益佰制药最新公告:选举窦启玲为董事长","url":"https://stock-news.laohu8.com/highlight/detail?id=2648017655","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648017655?lang=zh_cn&edition=full","pubTime":"2026-07-02 19:01","pubTimestamp":1782990098,"startTime":"0","endTime":"0","summary":"益佰制药(600594.SH)公告称,公司第九届董事会第一次会议审议通过选举窦启玲为董事长、窦雅琪为副董事长,并聘任窦雅琪为总经理,蒋先洪为董事会秘书,周弋、王化文、蒲健、蒋先洪为副总经理,曾宪体为副总经理兼财务负责人,周光欣为证券事务代表,任期三年。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200035023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0097","600594","BK0039","BK0077","BK0096","BK0239","BK0012","BK0070","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646315822","title":"每周股票复盘:益佰制药(600594)将召开临时股东会审议董监换届","url":"https://stock-news.laohu8.com/highlight/detail?id=2646315822","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646315822?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:00","pubTimestamp":1782586836,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,益佰制药报收于2.95元,较上周的3.11元下跌5.14%。本周关注点公司公告汇总:益佰制药将召开2026年第一次临时股东会审议董事会换届人选公司公告汇总:非独立董事候选人包括窦启玲、窦雅琪、曾宪体公司公告汇总:独立董事候选人名单为彭文宗、陈轩、梁亮公司公告汇总贵州益佰制药股份有限公司将于2026年7月2日召开2026年第一次临时股东会,采用现场与网络投票相结合方式。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000836.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0096","BK0077","600594","BK0097","BK0060","BK0070","BK0188","BK0039","BK0012","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646365444","title":"益佰制药(600594)披露2026年第一次临时股东会会议资料,6月26日股价下跌3.91%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646365444","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646365444?lang=zh_cn&edition=full","pubTime":"2026-06-26 22:40","pubTimestamp":1782484823,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,益佰制药报收于2.95元,较前一交易日下跌3.91%,最新总市值为23.36亿元。该股当日开盘3.07元,最高3.08元,最低2.94元,成交额达5804.48万元,换手率为2.45%。近日,贵州益佰制药股份有限公司披露《2026年第一次临时股东会会议资料》。公告显示,公司将于2026年7月2日召开2026年第一次临时股东会,采用现场与网络投票相结合方式。候选人简历及任职情况已在会议资料中披露,包括持股情况、关联关系及任职资格说明。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600045880.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","BK0012","BK0096","BK0077","BK0028","BK0039","BK0060","600594","BK0097","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643714763","title":"益佰制药(600594)披露2026年第一次临时股东会通知,6月16日股价下跌1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2643714763","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2643714763?lang=zh_cn&edition=full","pubTime":"2026-06-16 22:38","pubTimestamp":1781620698,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘,益佰制药报收于3.24元,较前一交易日下跌1.52%,最新总市值为25.66亿元。该股当日开盘3.29元,最高3.29元,最低3.19元,成交额达4465.84万元,换手率为1.75%。近日,贵州益佰制药股份有限公司发布《关于召开2026年第一次临时股东会的通知》。股权登记日为2026年6月25日,登记时间截至2026年7月1日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061600044361.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","600594","BK0097","BK0188","BK0060","BK0039","BK0028","BK0096","BK0012","BK0077","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637137577","title":"每周股票复盘:益佰制药(600594)拟注销753万回购股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2637137577","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2637137577?lang=zh_cn&edition=full","pubTime":"2026-05-24 04:20","pubTimestamp":1779567622,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘,益佰制药报收于3.72元,较上周的3.92元下跌5.1%。本周,益佰制药5月19日盘中最高价报3.92元。本周关注点来自公司公告汇总:益佰制药拟将已回购的7,533,500股股份注销,注册资本相应减少。贵州益佰制药股份有限公司于2026年4月至5月期间经董事会及年度股东大会决议,将已回购的7,533,500股股份用途由“用于员工持股计划或股权激励”变更为“用于注销并相应减少注册资本”。本次注销后,公司总股本将由791,927,400股调整为784,393,900股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400001333.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0039","BK0077","BK0070","BK0028","BK0012","600594","BK0060","BK0096","BK0188","BK0097"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636825511","title":"益佰制药(600594)披露变更回购股份用途并注销暨通知债权人公告,5月20日股价下跌2.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636825511","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636825511?lang=zh_cn&edition=full","pubTime":"2026-05-20 22:33","pubTimestamp":1779287597,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘,益佰制药报收于3.81元,较前一交易日下跌2.81%,最新总市值为30.17亿元。近日,贵州益佰制药股份有限公司发布《关于变更回购股份用途并注销暨通知债权人的公告》。公告显示,公司于2026年4月至5月期间召开董事会及年度股东大会,审议通过将已回购的7,533,500股股份用途由“用于员工持股计划或股权激励”变更为“用于注销并相应减少注册资本”。本次注销后,公司总股本将由791,927,400股变更为784,393,900股,注册资本相应减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000043443.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0039","BK0070","BK0097","600594","BK0077","BK0096","BK0239","BK0012","BK0060","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632977623","title":"每周股票复盘:益佰制药(600594)将举办2025年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2632977623","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2632977623?lang=zh_cn&edition=full","pubTime":"2026-05-02 06:09","pubTimestamp":1777673360,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,益佰制药报收于4.05元,较上周的4.33元下跌6.47%。本周关注点公司公告汇总:贵州益佰制药将于2026年5月11日举行2025年度业绩说明会,管理层将与投资者在线交流。公司公告汇总:益佰制药召开2025年年度股东会,审议利润分配预案、董事薪酬方案等多项议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0060","BK0239","BK0028","BK0039","BK0070","BK0097","600594","BK0077","BK0188","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631720655","title":"益佰制药(600594)披露将参加2026年贵州辖区上市公司投资者集体接待日活动暨2025年度业绩说明会,4月30日股价下跌1.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631720655","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631720655?lang=zh_cn&edition=full","pubTime":"2026-04-30 22:13","pubTimestamp":1777558399,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘,益佰制药报收于4.05元,较前一交易日下跌1.7%,最新总市值为32.07亿元。近日,贵州益佰制药股份有限公司发布《关于参加“2026年贵州辖区上市公司投资者集体接待日活动暨2025年度业绩说明会”的公告》。投资者可于公告发布日至2026年5月8日12:00前通过“贵州资本市场”微信公众号提交问题。公司已于2026年4月23日披露2025年年度报告,本次说明会将就财务状况、经营成果等与投资者交流。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000068743.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0097","600594","BK0039","BK0077","BK0096","BK0239","BK0012","BK0070","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787226924016,"stockEarnings":[{"period":"1week","weight":-0.0129},{"period":"1month","weight":0.1502},{"period":"3month","weight":0.0436},{"period":"6month","weight":-0.0449},{"period":"1year","weight":-0.1656},{"period":"ytd","weight":-0.0377}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":0.0259},{"period":"3month","weight":-0.0448},{"period":"6month","weight":-0.046},{"period":"1year","weight":0.0448},{"period":"ytd","weight":-0.0188}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"贵州益佰制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"45929人(较上一季度减少5.97%)","perCapita":"17078股","listingDate":"2004-03-23","address":"贵州省贵阳市云岩区白云大道220-1号","registeredCapital":"78439万元","survey":" 贵州益佰制药股份有限公司的主营业务是药品的研发、生产和销售,综合性医院、肿瘤专科医院、肿瘤放疗中心的运营与管理,开发、研制、生产及销售以苗药为特色的大健康产品。公司的主要产品是注射用洛铂、银杏达莫注射液、抗肿瘤类、心脑血管类、男科类、妇科类、其他、注射用瑞替普酶、科博肽、医疗服务、糖果、植物饮料、膏滋。","listedPrice":14.4},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"益佰制药(600594)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供益佰制药(600594)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"益佰制药,600594,益佰制药股票,益佰制药股票老虎,益佰制药股票老虎国际,益佰制药行情,益佰制药股票行情,益佰制药股价,益佰制药股市,益佰制药股票价格,益佰制药股票交易,益佰制药股票购买,益佰制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"益佰制药(600594)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供益佰制药(600594)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}